Urinary Incontinence News and Research RSS Feed - Urinary Incontinence News and Research

Urinary incontinence (UI), or the unintentional loss of urine, is a problem for more than 13 million Americans—85 percent of them women. Although about half of the elderly have episodes of incontinence, bladder problems are not a natural consequence of aging, and they are not exclusively a problem of the elderly.

Incontinence has several causes. Women are most likely to develop incontinence either during pregnancy and childbirth, or after the hormonal changes of menopause, because of weakened pelvic muscles. Older men can become incontinent as the result of prostate surgery. Pelvic trauma, spinal cord damage, caffeine, or medications including cold or over-the-counter diet tablets also can cause episodes of incontinence.

But even though urinary incontinence can be improved in 8 out of 10 cases, fewer than half of those with bladder problems ever discuss the condition with their health care professional. The condition often goes untreated.
Pfizer, Mylan enter settlement agreement to resolve generic Detrol LA litigation

Pfizer, Mylan enter settlement agreement to resolve generic Detrol LA litigation

Mylan Inc. today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Tolterodine Tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer's Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. [More]
ConvaTec enters definitive agreement to acquire 180 Medical

ConvaTec enters definitive agreement to acquire 180 Medical

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today it has entered into a definitive agreement to acquire all of the capital stock of 180 Medical Holdings, Inc. for $321 million. [More]

Children's Medical Center to broadcast two corrective bladder surgeries live on the internet

Children's Medical Center will help improve medical care for children around the world by broadcasting two surgeries live on the internet to help train doctors on the latest corrective bladder options. [More]
Uroplasty first quarter global sales increase 20% to $5.6 million

Uroplasty first quarter global sales increase 20% to $5.6 million

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the first quarter of fiscal 2013 ended June 30, 2012. [More]
Caregivers of stroke survivors are at risk for depression and complications from chronic stress

Caregivers of stroke survivors are at risk for depression and complications from chronic stress

Caregivers of stroke survivors are at risk for developing depression and complications from chronic stress, according to a study published by researchers at the Loyola University Chicago Marcella Niehoff School of Nursing (MNSON) in the latest issue of Biological Research for Nursing. [More]

Prostate patients make moves toward normality

A prompt return to usual daily activity is more likely for patients who have undergone radical prostatectomy if they start performing certain exercises soon after their operation, say researchers. [More]

Sling device a good shot for vaginal prolapse repair

A midurethral sling device added during surgery for vaginal prolapse repair reduces the risk for postoperative urinary incontinence, research shows. [More]

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning. [More]

Mid-urethral sling may reduce risk of urinary incontinence after surgery

For many adult women, supporting tissues in and around their vagina weaken to the point where the bladder and other organs descend from their normal position, creating a hernia into the vaginal wall known as pelvic organ prolapse. One in five women will undergo surgery to repair such prolapse. [More]

Midurethral slings can prevent pre-operative urinary incontinence in women with vaginal prolapse

A multicenter study involving a UT Southwestern Medical Center urogynecologist will eliminate some of the guesswork physicians face about whether to use a sling during vaginal prolapse repair to prevent urinary incontinence. [More]

US Court of Appeals confirms District Court decision in Watson's Sanctura XR patent suit

Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid. [More]
Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Pfizer Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for tafamidis meglumine. [More]

LUHS opens new center to treat women with pelvic-floor disorders

Loyola University Health System (LUHS) will open a multidisciplinary center to treat women with pelvic-floor disorders beginning today, Wednesday, June 13. [More]
First U.S.-based study to assess per-patient annual economic costs of fecal incontinence

First U.S.-based study to assess per-patient annual economic costs of fecal incontinence

Care for patients with fecal incontinence costs $4,110 per person for both medical and non-medical costs like loss of productivity, according to new research from the University of Michigan. [More]

Surprising life-quality benefit from early prostate cancer treatment

Treatment of early-stage prostate cancer may also improve quality of life if patients have previously suffered from obstructive urinary symptoms before undergoing treatment, shows US research. [More]

Doctors disagree on new prostate cancer screening guidelines

One doctor suggests the problem is the rush to treatment, not the screening; another suggests that a failure to screen men could be more costly in the long run. [More]
FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

Pfizer Inc. announced today that the United States Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted on Pfizer's clinical data package for tafamidis meglumine. [More]

PSA test benefits are questionable, yet physicians struggle to stop them

Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter serious pushback from primary care physicians, according to results of a survey by Johns Hopkins investigators. [More]

AUA includes percutaneous tibial nerve stimulation in OAB treatment guidelines

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for overactive bladder (OAB) treatment. [More]

Older, high-risk prostate cancer patients get better results in larger hospitals

Older, sicker, high-risk patients who undergo one of the most common treatments for prostate cancer get better results in larger, busier hospitals, according to new research by Henry Ford Hospital. [More]